|
Video: What is a Stock Split?
|
|
AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies to address pandemics and common diseases. Co.'s full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. Rather than advancing its own clinical pipeline of drug candidates, Co. forges partnerships with drug developers of all sizes, from pharmaceutical to small biotechnology companies. In a collaboration with Eli Lilly and Company, Co. has applied its technology stack to co-develop LY-CoV555, a potential antibody therapy to treat and prevent COVID-19. According to our AbCellera Biologics stock split history records, AbCellera Biologics has had 2 splits. | |
|
AbCellera Biologics (ABCL) has 2 splits in our AbCellera Biologics stock split history database. The first split for ABCL took place on November 14, 1995. This was a 5 for 4
split, meaning for each 4
shares of ABCL owned pre-split, the shareholder now owned 5 shares. For example, a 1000 share position pre-split, became a 1250 share position following the split. ABCL's second split took place on September 29, 1997. This was a 3 for 2
split, meaning for each 2
shares of ABCL owned pre-split, the shareholder now owned 3 shares. For example, a 1250 share position pre-split, became a 1875 share position following the split.
When a company such as AbCellera Biologics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the AbCellera Biologics stock split history from start to finish, an original position size of 1000 shares would have turned into 1875 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AbCellera Biologics shares, starting with a $10,000 purchase of ABCL, presented on a split-history-adjusted basis factoring in the complete AbCellera Biologics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/14/2020 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$50.01 |
|
End price/share: |
$3.63 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-92.74% |
|
Average Annual Total Return: |
-54.17% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$725.95 |
|
Years: |
3.36 |
|
|
|
Date |
Ratio |
11/14/1995 | 5 for 4
| 09/29/1997 | 3 for 2
|
|
|